Theranostics the key to UK drugs access?
This article was originally published in Clinica
Executive Summary
The growing healthcare potential of theranostics has been thrust into a UK debate on access to new drugs through the NHS. After the National Institute for Health and Clinical Excellence (NICE) rejected four products for the management of advanced renal cancer on the grounds of insufficient clinical and/or cost-effectiveness, oncology experts noted that better targeting of patients would make these drugs viable by improving response and effectiveness rates. In turn, this would reduce the waste of resources that results from ineffective treatment. In the case of the pharmaceutical products involved in the appraisal (Sutent, Avastin, Nexavar and Torisel), they reportedly exceeded NICE's usual cost-effectiveness threshold – £30,000 ($55,000) per quality-adjusted life year (QALY) – by a factor of six. Advanced renal cancer is diagnosed in around 3,600 people per year.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.